<DOC>
	<DOCNO>NCT00359021</DOCNO>
	<brief_summary>The purpose trial evaluate long-term safety tolerability TMC125 200 mg twice daily part antiretroviral therapy include TMC114/rtv investigator select optimized background HIV-1 infect patient participate DUET trial ( TMC125-C206 TMC125 C216 ) meet definition virologic failure Week 24 later trial .</brief_summary>
	<brief_title>An Open-label Trial With TMC125 Patients Who Have Virologically Failed DUET Trial ( TMC125-C206 TMC125-C216 ) .</brief_title>
	<detailed_description>This Phase III open-label , roll-over trial evaluate long term tolerability , safety , antiviral immunological effect TMC125 part individually optimized antiretroviral therapy include TMC114/rtv HIV-1 infect patient participate one DUET ( TMC125-C206 TMC125-C216 ) trial . Also change HIV-1 resistance time evaluate . This trial offer patient meet definition virologic failure Week 24 beyond option roll-over open-label trial receive TMC125 TMC114/rtv . Three hundred patient estimate enroll trial . The withdrawal visit DUET trial first visit trial . From visit onward , patient receive 200 mg twice daily TMC125 600/100 mg twice daily TMC114/rtv TMC114 TMC125 commercially available therapy longer clinical benefit patient . Patients receive antiretroviral therapy consist TMC125 non-nucleoside reverse transcriptase inhibitor ( NNRTI ) , TMC114/rtv protease inhibitor ( PI ) optimize background , select investigator accord local standard care , patient 's experience previous therapy recent resistance testing . The recent HIV-1 genotype-analysis system report result DUET trial make available . TMC125 dose 200 mg twice daily , administer orally 2 tablet twice daily food.TMC114/rtv dose 600/100 mg twice daily , administer orally 2 tablet TMC114 1 capsule ritonavir twice daily food.The optimize background comprise least 1 approved ARV drug : 1 NRTI ( ) , without ENF . Administration continue TMC114 TMC125 commercially available therapy longer clinical benefit patient .</detailed_description>
	<mesh_term>Etravirine</mesh_term>
	<criteria>Patient previously randomize DUET ( TMC125C206 TMC125C216 ) trial complete least 24 week treatment Patient virologically fail DUET trial . Use disallow concomitant therapy Any grade 4 toxicity accord Division AIDS ( DAIDS ) grade table Patients withdraw DUET ( TMC125C206 TMC125C216 ) trial mandatory withdrawal criterion trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>HIV-1</keyword>
	<keyword>treatment experience</keyword>
	<keyword>virologic failure</keyword>
</DOC>